NCT02240212View on ClinicalTrials.gov

Study of Afuresertib Combined With Paclitaxel in Gastric Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

February 7, 2017

Study Completion Date

February 7, 2017

Conditions
Cancer
Interventions
DRUG

Afuresertib

The unit dose strength is 50mg/75mg tablet. Afuresertib will be taken orally once daily continuously during trail.

DRUG

Paclitaxel

Paclitaxel sourced locally will be administered IV

Trial Locations (5)

100

Novartis Investigative Site, Taipei

112

Novartis Investigative Site, Taipei

110-774

Novartis Investigative Site, Seoul

120/752

Novartis Investigative Site, Seoul

135-710

Novartis Investigative Site, Seoul

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY